Original Article

CME Article: Safety of Recombinant Zoster Vaccine in Rheumatology Patients

Authors: Syed Raza, MD, Saurav Acharya, MD, Gabrielle Howard, MD, Debendra Pattanaik, MD


Objectives: Recombinant zoster vaccine (RZV) is Food and Drug Administration approved for the prevention of herpes zoster (shingles) in adults 50 years old and older. Immunocompromised subjects were excluded from the pivotal vaccine trials. We studied the safety of this vaccine in our university-affiliated rheumatology practice.

Methods: This was a single-center, retrospective study focusing on subjects who received RZV during 2018. We collected the demographic data, any self-reported adverse events after vaccination, C-reactive protein, Routine Assessment of Patient Index Data 3 (RAPID3) scores for subjects with rheumatoid arthritis, and available RAPID3 scores for all study subjects before and after the vaccination.

Results: Comparision of C-reactive protein (n = 40), RAPID3 scores for subjects with rheumatoid arthritis (n = 16), and available RAPID3 scores for all subjects (n = 21) using the paired t test, did not show significant differences before and after the administration of RZV. A total of 6.4% of patients reported adverse events after vaccination. The adverse events were mild and did not lead to hospitalization, end organ damage, or change in treatment plan.

Conclusions: The RZV was safe and well tolerated among our study population.
Posted in: Rheumatology and Orthopedics18

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc 2016;9:447–454.
2. Buchan SA, Daneman N, Wang J, et al. Incidence of hospitalizations and emergency department visits for herpes zoster in immunocompromised and immunocompetent adults in Ontario, Canada, 2002–2016. Clin Infect Dis 2020;71:22–29.
3. McKay SL, Guo A, Pergam SA, et al. Herpes zoster risk in immunocompromised adults in the United States: a systematic review.Clin Infect Dis 2020;71:e125–e134.
4. Lachiewicz AM, Srinivas ML. Varicella-zoster virus post-exposure management and prophylaxis: a review. Prev Med Rep 2019;16:101016.
5. Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis 2008;197(suppl 2):S58–S60.
6. Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc 2017;92:1806–1821.
7. Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 2017;69:1960–1968.
8. Marra F, Lo E, Kalashnikov V, et al. Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis. Open Forum Infect Dis 2016;3:ofw205.
9. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087–2096.
10. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375:1019–1032.
11. Bharucha T, Ming D, Breuer J. A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother 2017;13:1789–1797.
12. Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 2014; 32:1745–1753.
13. Walsh N. Questions remain about Shingrix safety in rheumatic disease. https:// www.medpagetoday.com/meetingcoverage/oar/74765. Published August 26, 2018. Accessed December 7, 2021.
14. Stevens E, Weinblatt ME, Massarotti E, et al. Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a Single center's experience with 400 patients. ACR Open Rheumatol 2020;2:357–361.
15. Lenfant T, Jin Y, Kirchner E, et al. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. Rheumatology (Oxford) 2021;60:5149–5157.
16. Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2014;66:1016–1026.
17. Di Pasquale A, Preiss S, Tavares Da Silva F, et al. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel) 2015;3:320–343.
18. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee. Briefing Document for HZ/ su (Zoster Vaccine Recombinant, Adjuvanted). Advisory Committee Meeting, 2017. https:// www.fda.gov/media/107553/download. Accessed January 5, 2022.
19. Satyam VR, Li PH, Reich J, et al. Safety of recombinant zoster vaccine in patients with inflammatory bowel disease. Dig Dis Sci 2020;65: 2986–2991.
20. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016;68:1–26.
21. Centers for Disease Control and Prevention. Shingles (herpes zoster). Vaccination. https://www.cdc.gov/shingles/vaccination.html. Published 2019. Accessed December 7, 2021.
22. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79:39–52